Hospira Propofol Injectable Emulsion: Recall- Glass Vial Defect

by FDA on August 16, 2012

in MedWatch

Risks associated with this defect could include tissue necrosis in one or more organs that could result in stroke, myocardial infarction, respiratory failure, and loss of renal and hepatic function.

This is a summary of an alert issued by MedWatch: The FDA Safety Information and Adverse Event Reporting Program. The link below will take you to the original notice.

View Full Details Of The Original MedWatch Notice Here.

Leave a Comment

Previous post:

Next post: